Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listZoledronic acid

Zoledronic acid

Synonym(s):[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate;P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate;Zoledronate monohydrate;Zoledronic acid monohydrate

  • CAS NO.:118072-93-8
  • Empirical Formula: C5H10N2O7P2
  • Molecular Weight: 272.09
  • MDL number: MFCD00867791
  • EINECS: 1806241-263-5
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-10-25 16:21:11
Zoledronic acid Structural

What is Zoledronic acid?

Absorption

A 4mg intravenous dose reaches a Cmax of 370±78.5ng/mL, with a Tmax of 0.317±0.014h, and an AUC of 788±181ng*h/mL. A 5mg intravenous dose reaches a Cmax of 471±76.1ng/mL, with a Tmax of 0.368±0.005h, and an AUC of 917±226ng*h/mL.

Toxicity

Patients experiencing an overdose may present with renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Overdose should be managed through intravenous administration of the insufficient ions.

Description

Zoledronic acid is a white, crystalline powder that is available in vials for reconstitution for IV infusion over at least 15 minutes. It does not undergo metabolic transformation and does not inhibit CYP450 enzymes. Clearance of this agent is dependent on the patient's creatinine clearance, not on dose. Serum creatinine levels should be evaluated before every treatment. Zolendronic acid is contraindicated in patients with severe renal impairment.

Chemical properties

White Solid

Originator

Zometa,Novartis Pharma,Switz

The Uses of Zoledronic acid

Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.

The Uses of Zoledronic acid

Bisphosphonate antiresorptive agent

The Uses of Zoledronic acid

bone resorption inhibitor

What are the applications of Application

Zoledronic acid, anhydrous is a protein kinase C activator with apoptotic effects

Background

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.

Indications

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Definition

ChEBI: An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.

Manufacturing Process

With stirring and under reflux, 8.6 g (0.053 mole) of imidazol-4-yl acetic acid hydrochloride, 7.1 ml of 85% phosphoric acid and 25 ml of chlorobenzene are heated to 100°C. Then 13.9 ml of phosphorus trichloride are added dropwise at 100°C, whereupon evolution of gas occurs. Over the course of 30 min a dense mass precipitates from the reaction mixture. The batch is heated for 3 hours to 100°C and the supernatant chlorobenzene is removed by decantation. With stirring and under reflux, the residual viscous mass is heated to the boil for 3 hours with 40 ml of 9 N hydrochloric acid. The batch is filtered hot with the addition of carbon and the filtrate is diluted with acetone, whereupon the crude 2-(imidazol-4-yl)-1-hydroxy-ethane-1,1- diphosphonic acid precipitates. This product is recrystallised from water. Melting point: 238-240°C (dec.).

brand name

Zometa (Novartis).

Therapeutic Function

Bone calcium regulator

Biological Functions

Zoledronic acid, a bisphosphonate, was approved by the U.S. FDA in 2001 for the treatment of hypercalcemia of malignancy, a metabolic complication that can be life-threatening. Hypercalcemia of malignancy can occur in up to 50% of patients diagnosed with advanced breast cancer, multiple myeloma, and nonsmall cell lung cancer. This condition arises when chemical moieties produced by the tumor cause overstimulation of osteoclasts. When there is an increase in bone degradation, there is a concomitant release of calcium into the plasma. When serum concentrations of calcium rapidly elevate, the kidneys are unable to handle the overload, and hypercalcemia results. This can lead to dehydration, nausea, vomiting, fatigue, and confusion. Zoledronic acid effectively decreases plasma calcium concentrations via inhibition of bone resorption (inhibition of osteoclastic activity and induction of osteoclast apoptosis). It also prevents the increase in osteoclastic activity caused by tumor-based stimulatory factors. Additionally zoledronic acid has been approved by the U.S. FDA for the treatment of multiple myeloma and bone metastases associated with solid tumor–based cancers (e.g., prostrate and lung). This agent is currently in late-stage clinical trials for the treatment and prevention of osteoporosis and, if approved, will be formulated as a 5-mg, once-yearly IV infusion.

Pharmacokinetics

Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption. The therapeutic window is wide as patients are unlikely to suffer severe effects from overdoses and the duration of action is long. Patients should be counselled regarding the risk of electrolyte deficiencies, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, bronchoconstriction, hepatic impairment, hypocalcemia, and embryo-fetal toxicity.

Clinical Use

Zoledronic acid is most commonly given to patients whose cancer is no longer responding to hormones, but it also may be given to prevent the bone thinning and weakening that results from hormonal treatments.

Drug interactions

Potentially hazardous interactions with other drugs
Other nephrotoxic drugs: use with caution as can enhance nephrotoxicity

Metabolism

Zoledronic acid is not metabolized in vivio.

Metabolism

Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 ± 16
% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue.

storage

Store at +4°C

References

1) Green?et al. (1994),?Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound; J. Bone Miner. Res.,?9?745 2) Deeks and Perry (2008)?Zoledronic acid: a review of its use in the treatment of osteoporosis; Drugs Aging,?25?963 3) Perry and Figgitt (2004),?Zoledronic acid: a review of its use in patients with advanced cancer; Drugs,?64?1197 4) Koto?et al. (2010)?Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis and shows combined effects with other anticancer agents; Oncol. Rep.,?24?233 5) Tonyali?et al. (2010)?The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives; Expert Opin. Pharmacother.,?11?2715

Properties of Zoledronic acid

Melting point: 193-2040C (dec)
Boiling point: 764.0±70.0 °C(Predicted)
Density  2.13±0.1 g/cm3(Predicted)
storage temp.  Sealed in dry,Room Temperature
solubility  Soluble in Water (up to 2 mg/ml).
form  solid
pka 1.41±0.10(Predicted)
color  White or off-white
Stability: Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 2 months.
CAS DataBase Reference 118072-93-8(CAS DataBase Reference)

Safety information for Zoledronic acid

Computed Descriptors for Zoledronic acid

Abamectin manufacturer

USV Pvt Ltd

1Y
Phone:+91-2225564048
product: Zoledronic Acid 98%
Inquiry

Cipla Ltd

1Y
Phone:+912224826000
product: Zoledronic Acid 118072-93-8 98%
Inquiry

Hetero Drugs Limited

1Y
Phone:+914023704923
product: 118072-93-8 Zoledronic Acid 98%
Inquiry

Sun Pharmaceutical Industries Ltd

1Y
Phone:+912243244324
product: 118072-93-8 98%
Inquiry

Shilpa Medicare Limited (SML)

1Y
Phone:+91-9320649838
Whatsapp: +91-9320649838
product: Zoledronic Acid 99%
Inquiry

Basil Drugs AND Pharmaceuticals Pvt Ltd

1Y
Phone:+91-9619320820
Whatsapp: +91 9619320820
product: Zoledronic Acid 118072-93-8 98%
Inquiry

NATCO Pharma Limited

1Y
Phone:+91-9866005199
Whatsapp: +91 9866005199
product: 118072-93-8 Zoledronic Acid 98%
Inquiry

ALS INDIA LIFE SCIENCES

1Y
Phone:+91-8977036379
Whatsapp: +91 8008166674
product: 118072-93-8 98%
Inquiry

Kekule Pharma Limited

1Y
Phone:+919849798889
Whatsapp: +91 9849798889
product: Zoledronic Acid 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.